AstraZeneca: positive results in type-2 diabetes

(CercleFinance.com) - Farxiga significantly reduced hospitalisation for heart failure or cardiovascular events death in patients with type-2 diabetes in a clinical trial, AstraZeneca said on Monday.


Results from the study, which has over 17,000 patients across 33 different countries, showed that Farxiga significantly cut the risk of hospitalisation for heart failure or cardiovascular death composite vs. placebo by 17%.

In addition, there were fewer major adverse cardiovascular events observed with Farxiga, although this did not reach statistical significance (8.8% for Farxiga vs. 9.4% for placebo).

Patients with type-2 diabetes have a two-to-five times greater risk of heart failure, along with an increased risk of a heart attack or stroke.

The full data was presented at the American Heart Association (AHA) Scientific Sessions 2018 in Chicago, and simultaneously published in the New England Journal of Medicine.

Copyright (c) 2018 CercleFinance.com. All rights reserved.